REVELATION BIOSCIENCES, INC.

Revelation Biosciences, Inc. (Nasdaq: REVB) is a clinical-stage biotechnology company focused on modulating the innate immune system to address infectious disease and other unmet medical needs. The company reached the public markets through its merger with Petra Acquisition Inc., a blank-check special purpose acquisition company that completed its IPO in 2021, with the de-SPAC transaction closing in 2023. REVB operates in the healthcare and life sciences sector and has been listed on Nasdaq following the combination. The company filed a Form 8-K with the Securities and Exchange Commission on August 19, 2026, disclosing a material corporate event. Investors and analysts seeking comprehensive filing history, deal terms, and SPAC-related data on Revelation Biosciences can sign up for full access at SpacDesk.